Kjersti Helene Hernæs1,2, Knut B Smeland3, Unn-Merete Fagerli4,5, Cecilie E Kiserud3. 1. Norwegian Institute of Public Health, PO Box 222, Skøyen, N-0213, Oslo, Norway. KjerstiHelene.Hernaes@fhi.no. 2. Previous affiliation: Research Support Services, Oslo University Hospital, Sogn Arena, Klaus Torgårds vei 3, 3. Floor, 0372, Oslo, Norway. KjerstiHelene.Hernaes@fhi.no. 3. National Advisory Unit for Late Effects after Cancer Treatment, Oslo University Hospital, Radiumhospitalet, PO 4953, Nydalen, N-0424, Oslo, Norway. 4. Department of Oncology, St. Olavs hospital HF, Postboks 3250 Torgarden, 7006, Trondheim, Norway. 5. Institute for Clinical and Molecular Medicine (IKOM), The Norwegian University of Science and Technology (NTNU), Olav kyrres gate 9, 7006, Trondheim, Norway.
Abstract
BACKGROUND: This study describes post-treatment work patterns in lymphoma survivors treated with high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). It aims to identify determinants for labour force participation and exclusion after HDT-ASCT. METHODS: All survivors treated with HDT-ASCT for lymphoma in Norway between 1995 and 2008, aged ≥18 years at HDT-ASCT and alive at survey in 2012-2013 were eligible. We divide survivors by current employment status (full-time, part-time and unemployed). Main outcomes are current employment status, work hours and work ability. Withdrawals are patients employed when diagnosed but not before HDT-ASCT. RESULTS: Of the 274 who completed the survey, 82% (N = 225) were included in the final analyses. Mean age at survey was 52 years, 39% were female, 85% were employed when diagnosed, 77% before HDT-ASCT and 69% at survey. Employment before HDT-ASCT corresponds with a higher probability of employment at survey for a given symptom burden. In the most extensive statistical model, it increases with 37.3 percentage points. Work hours amongst withdrawals plummet after HDT-ASCT while work ability shows a rebound effect. The potential economic gain from their re-enter into the work force equals 70% of the average annual wage in Norway in 2012. CONCLUSIONS: For a given symptom burden, staying employed throughout diagnosis and treatment is associated with a higher probability of future employment. These results favour policies for labour force inclusion past diagnosis and treatment increasing cancer survivors' probability of future employment. However, we need more research on withdrawal mechanisms, and on policy measures that promote inclusion.
BACKGROUND: This study describes post-treatment work patterns in lymphoma survivors treated with high-dose chemotherapy with autologous stem-cell transplantation (HDT-ASCT). It aims to identify determinants for labour force participation and exclusion after HDT-ASCT. METHODS: All survivors treated with HDT-ASCT for lymphoma in Norway between 1995 and 2008, aged ≥18 years at HDT-ASCT and alive at survey in 2012-2013 were eligible. We divide survivors by current employment status (full-time, part-time and unemployed). Main outcomes are current employment status, work hours and work ability. Withdrawals are patients employed when diagnosed but not before HDT-ASCT. RESULTS: Of the 274 who completed the survey, 82% (N = 225) were included in the final analyses. Mean age at survey was 52 years, 39% were female, 85% were employed when diagnosed, 77% before HDT-ASCT and 69% at survey. Employment before HDT-ASCT corresponds with a higher probability of employment at survey for a given symptom burden. In the most extensive statistical model, it increases with 37.3 percentage points. Work hours amongst withdrawals plummet after HDT-ASCT while work ability shows a rebound effect. The potential economic gain from their re-enter into the work force equals 70% of the average annual wage in Norway in 2012. CONCLUSIONS: For a given symptom burden, staying employed throughout diagnosis and treatment is associated with a higher probability of future employment. These results favour policies for labour force inclusion past diagnosis and treatment increasing cancer survivors' probability of future employment. However, we need more research on withdrawal mechanisms, and on policy measures that promote inclusion.
Entities:
Keywords:
Employment; HDT-ASCT; Late effects; Lymphoma; Withdrawal; Work ability
Authors: Knut Bjøro Smeland; Cecilie E Kiserud; Grete F Lauritzsen; Anne Kirsti Blystad; Unn Merete Fagerli; Øystein Fluge; Alexander Fosså; Jens Hammerstrøm; Arne Kolstad; Jon Håvard Loge; Martin Maisenhølder; Bjørn Østenstad; Stein Kvaløy; Harald Holte Journal: Tidsskr Nor Laegeforen Date: 2013-09-03
Authors: Alv A Dahl; Sophie D Fosså; Hanne C Lie; Jon Håvard Loge; Kristin Valborg Reinertsen; Ellen Ruud; Cecilie Essholt Kiserud Journal: J Adolesc Young Adult Oncol Date: 2019-03-22 Impact factor: 2.223